Status:
RECRUITING
Discovery of Soluble Biomarkers for Pancreatic Cancer Using Innovative All-Patient Inclusive Methodology
Lead Sponsor:
University Hospital, Montpellier
Conditions:
Pancreatic Neoplasms
Eligibility:
All Genders
18+ years
Brief Summary
Pancreatic ductal adenocarcinoma (PDAC) remains among cancers with a very poor prognosis (1-year survival \<20%). Endoscopic ultrasound with fine needle aspiration (EUS/FNA) is the common examination ...
Detailed Description
Clinical and pathological data will be prospectively collected to obtain 2 subgroups: PDAC and non-PDAC according to the final biopsy diagnosis. A combined quantitative analysis of the proteins and th...
Eligibility Criteria
Inclusion
- Patient with pancreatic mass and suspicion of pancreatic ductal adenocarcinoma requiring endoscopic ultrasound with fine needle biopsy
Exclusion
- Vulberable person according to L1121-6 of Public health reglementation in France
- Pregnant women
Key Trial Info
Start Date :
January 14 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2025
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04370574
Start Date
January 14 2021
End Date
July 1 2025
Last Update
July 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Uh Montpellier
Montpellier, Montpellier, France, 34280